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Gustave Roussy Campus Cancer, University Paris-Sud, Villejuif, FranceThus far the development of adjuvant therapies in mela-noma has suffered greatly from the lack of effective drugs
for stage IV melanoma. This has led to adjuvant therapies
that are not uniformly used because of rather marginal
benefits.
1. Adjuvant therapies other than with
interferon
1.1. Early trials with immune stimulants
More than 25 randomised trials have been conducted in stage
II/III melanoma with non-specific immune stimulants – such
as BCG (bacillus Calmette–Guerin), Corynebacterium parvum,
levamisole or combinations of these agents with dacarbazine
– without identifying clear benefits [1].
1.2. Adjuvant vaccine trials
Adjuvant vaccine trials in melanoma thus far have failed, re-
sults ranging from ineffective (three randomized controlled
trial (RCTs) [1]) to harmful (three RCTs [2–4]). Two large trials
with Canvaxin ended early because of a detrimental outcome
for the vaccine arm. Two large trials with the GMK vaccine
(ganglioside GM2/KLH/QS-21) were also stopped early because
of inferior outcome in the vaccine arms compared with high-
dose interferon (HDI) in the Eastern Cooperative Oncology
Group (ECOG) 1694 trial [3] and compared with observation
in stage II patients (European Organisation for Research and
Treatment of Cancer (EORTC) 18961 trial) [4], evoking fears
that prolonged, multiple administrations of vaccines could
be harmful [5].
Regarding the adjuvant use of granulocyte–monocyte col-
ony-stimulating factor (GM-CSF), a recent report of the ECOG
E4697 trial failed to demonstrate a significant impact on sur-
vival [6]. In two randomised trials the GM-CSF-containing
arms did worse than the vaccine-alone arms [7,8], again indi-
cating that multiple vaccinations might be harmful.
New vaccine trials are ongoing. The MAGE-A3 protein
combined with the immunostimulant AS15 is being evaluated
in an RCT in stage III patients after encouraging results were
obtained in a randomised phase II EORTC trial [9]. Moreover,
a potentially predictive gene profile, characterising mostly
immunomodulatory factors, is used to stratify and analysethe results of the RCT [10]. Also a study of an oncolytic herpes
simplex virus vector encoding GM-CSF is ongoing in stage III/
IV patients after interesting results in phase II patients were
obtained [11,12].
1.3. Adjuvant therapy with interferon
Twenty-five years of RCTs in melanomawith interferon-alpha
(IFNa) are a testimony that efficacy of adjuvant therapy with
IFN is modest at best. Meta-analyses of phase III trials demon-
strated that IFN has a consistent effect on relapse-free sur-
vival (RFS) but no or only a marginal effect on overall
survival (OS) [13–15]. No relationship between dose or dura-
tion of treatment and outcome has been demonstrated. These
findings suggest that only a minority of patients are sensitive
to IFN, and demand that we identify these patients. Based on
the EORTC 18991 trial in 1256 patients, the US Food and Drug
Administration (FDA) approved pegylated interferon a-2b
(PEG-IFN; SylatronTM) in 2011 for stage III melanoma patients
[16]. The EORTC 18952 trial in 1388 stage IIB/III melanoma pa-
tients compared intermediate doses of interferon a-2b (IFN)
with observation [17].
These EORTC RCTs stratified patients by SN-staging
(microscopic involvement only: stage III-N1) or gross macro-
scopic relapse (stage III-N2) as well as by presence or absence
of ulceration in the primary tumour. Both stage and ulcera-
tion are key prognostic factors [32]. Patients with only
micrometastases have a much better prognosis than patients
with palpable node metastases [18]. Palpable nodal disease
may represent more aggressive disease from the onset or by
acquisition of additional mutations over time. Regarding
ulceration, for the same Breslow thickness, patients with an
ulcerated primary have a 10–25% lower survival probability
at 10 years, indicating a distinct biological entity [19]. Also,
ulcerated primaries have (a) a distinct gene profile [20]; (b) a
severely immunosuppressed status of sentinel nodes [21]
and (c) a different stromal response [22].
The meta-analysis of the two largest adjuvant IFN/PEG-IFN
RCTs involving 2644 patients demonstrated that both tumour
load in the lymph nodes and ulceration of the primary are
independent predictive factors for adjuvant IFN therapy [23].
Patients with favourable stage (IIb/III-N1) and/or ulcerated
primary tumour benefited significantly from IFN/PEG-IFN
treatment (hazard ratios (HRs) 0Æ56–0Æ69) with regard to RFS,
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tients with stage III-N2 disease or non-ulcerated primary tu-
mour did not. Ulceration of the primary was the
overridingly important predictive factor for IFN sensitivity.
In a meta-analysis of 1393 patients with ulcerated melano-
mas – reported in a variety of trials that did not include
EORTC 18991 – Wheatley et al reported a hazard ratio (HR)
of adjuvant IFN therapy for OS of 0.77 (99% confidence inter-
val (CI) 0.63–0.93), whilst there was no impact of adjuvant
IFN therapy in the 2118 patients without ulceration (HR 0.98;
99% CI 0.87–1.17) [23]. Treatment interaction between ulcera-
tion and IFN has been investigated retrospectively in the Sun-
belt and the Nordic trials [24,25]. In the Sunbelt trial, which
enrolled SN-positive patients only, a significant treatment
benefit occurred only in patients with ulcerated primaries
[24]. In the Nordic trial, almost all patients had palpable nodal
involvement and, consistently with the EORTC trials, no sig-
nificant benefit was conferred by the presence of ulceration
[25]. The role of ulceration is currently being evaluated pro-
spectively in the adjuvant PEG-IFN trial EORTC 18081 in 1200
patients with stage II ulcerated primary melanomas.
Research on tissue samples to identify gene profiles and
cytokine profiles potentially predictive for IFN sensitivity is
ongoing [26]. In contrast to findings by Gogas and Kirkwood
[27], the prognostic and potentially predictive value of the
presence of autoimmune antibodies in the EORTC and Nordic
trials was evaluated and found not to be a strong prognostic
factor, neither did it have predictive value [28,29].
In 2012, the results of the adjuvant phase III trial of
adjuvant biochemotherapy (CVD + IL2 + IFN) demonstrated a
significant improvement in RFS but no improvement in
OS. These results are interesting but not practice-changing
[30].2. New adjuvant trials with novel agents
2.1. Immunomodulators
For patients with advanced stage III melanoma, a double-
blind RCT comparing adjuvant ipilimumab versus placebo re-
cently completed accrual of 950 patients (EORTC 18071; Clin-
icalTrials.gov, number NCT00636168) [31]. Preliminary data
from another small trial suggest adjuvant ipilimumab activity
in advanced resected stage III/IV disease [32]. New adjuvant
trials evaluating anti-PD-1 are being prepared.2.2. BRAF inhibitors and MEK inhibitors
New adjuvant trials in lymph-node-positive melanoma pa-
tients have been launched involving BRAF inhibitors either
alone or in combination with MEK inhibitors [33,34]. The basis
for these trials is their success in stage IV patients. Trials
are ongoing, and design and pros and cons will be
discussed.Conflict of interest statement
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